These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 31342434)
1. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Gatto F; Campana C; Cocchiara F; Corica G; Albertelli M; Boschetti M; Zona G; Criminelli D; Giusti M; Ferone D Rev Endocr Metab Disord; 2019 Sep; 20(3):365-381. PubMed ID: 31342434 [TBL] [Abstract][Full Text] [Related]
2. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Christofides EA Patient Prefer Adherence; 2016; 10():1217-25. PubMed ID: 27471378 [TBL] [Abstract][Full Text] [Related]
3. LIMITATIONS OF CURRENT APPROACHES FOR THE TREATMENT OF ACROMEGALY. Shanik MH Endocr Pract; 2016 Feb; 22(2):210-9. PubMed ID: 26437214 [TBL] [Abstract][Full Text] [Related]
9. Current treatment guidelines for acromegaly. Melmed S; Jackson I; Kleinberg D; Klibanski A J Clin Endocrinol Metab; 1998 Aug; 83(8):2646-52. PubMed ID: 9709926 [TBL] [Abstract][Full Text] [Related]
10. [Current diagnosis and treatment of acromegaly]. Melgar V; Espinosa E; Cuenca D; Valle V; Mercado M Rev Med Inst Mex Seguro Soc; 2015; 53(1):74-83. PubMed ID: 25680646 [TBL] [Abstract][Full Text] [Related]
11. The Modern Criteria for Medical Management of Acromegaly. Frara S; Maffezzoni F; Mazziotti G; Giustina A Prog Mol Biol Transl Sci; 2016; 138():63-83. PubMed ID: 26940387 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Selvarajah D; Webster J; Ross R; Newell-Price J Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912 [TBL] [Abstract][Full Text] [Related]
13. Acromegaly: clinical features at diagnosis. Vilar L; Vilar CF; Lyra R; Lyra R; Naves LA Pituitary; 2017 Feb; 20(1):22-32. PubMed ID: 27812777 [TBL] [Abstract][Full Text] [Related]
14. How effective are current therapies for acromegaly? Freda PU Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological therapy for acromegaly: a critical review. Muller AF; Van Der Lely AJ Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564 [TBL] [Abstract][Full Text] [Related]
16. Pegvisomant: an advance in clinical efficacy in acromegaly. Stewart PM Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298 [TBL] [Abstract][Full Text] [Related]
17. Advances in the pharmacotherapy of patients with acromegaly. Fleseriu M Discov Med; 2014 Jun; 17(96):329-38. PubMed ID: 24979253 [TBL] [Abstract][Full Text] [Related]
18. Management of acromegaly: is there a role for primary medical therapy? Bush ZM; Vance ML Rev Endocr Metab Disord; 2008 Mar; 9(1):83-94. PubMed ID: 18163213 [TBL] [Abstract][Full Text] [Related]
19. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM; Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536 [TBL] [Abstract][Full Text] [Related]
20. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Doga M; Bonadonna S; Burattin A; Giustina A Ann Oncol; 2001; 12 Suppl 2():S89-94. PubMed ID: 11762359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]